<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Asthma in children younger than 12 years: Management of persistent asthma with controller therapies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Asthma in children younger than 12 years: Management of persistent asthma with controller therapies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Asthma in children younger than 12 years: Management of persistent asthma with controller therapies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Sawicki, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenan Haver, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert A Wood, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Redding, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of long-term controller medications in the treatment of persistent asthma in children &lt;12 years of age is reviewed here. The recommendations that follow are based upon major published asthma guidelines [
         <a href="#rid1">
          1-4
         </a>
         ], with additional therapies added as they become available and approaches modified based upon subsequently published data. Assessing initial asthma severity, determining when to start daily controller therapy, and assessing and monitoring control to determine if therapy modifications are needed are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p>
         The initial evaluation and diagnosis of asthma, use of quick-relief medications, and management of acute exacerbations in children are all discussed separately. A general overview of asthma management and control of triggers are also presented separately, as is the management of asthma in adolescents and adults.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5742.html" rel="external">
          "Asthma in children younger than 12 years: Initial evaluation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/562.html" rel="external">
          "Trigger control to enhance asthma management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/527.html" rel="external">
          "Initiating asthma therapy and monitoring in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/532.html" rel="external">
          "Ongoing monitoring and titration of asthma therapies in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3787443798">
         <span class="h1">
          GOALS OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overarching goals of treatment are to maintain control of asthma symptoms and reduce exacerbations with the least amount of medications and fewest side effects.
        </p>
        <p class="headingAnchor" id="H1468401982">
         <span class="h1">
          TYPES OF CONTROLLER MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly used controller medications for children &lt;12 years of age are inhaled glucocorticoids (also called inhaled corticosteroids [ICS]), plus inhaled long-acting beta agonists (LABAs) or oral leukotriene receptor antagonists (LTRAs) in combination with inhaled glucocorticoids  (
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ). Long-acting anticholinergic agents (or long-acting muscarinic antagonists [LAMAs];
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         , for children ≥6 years of age) and biologic agents (monoclonal antibodies against immunoglobulin E [IgE] and interleukin [IL] 5, for children ≥6 years of age  (
         <a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">
          table 3
         </a>
         )) are used as step-up therapy in patients whose asthma is not well controlled on other medications. Oral glucocorticoids; inhaled chromones (in the United States,
         <a class="drug drug_pediatric" data-topicid="12632" href="/z/d/drug information/12632.html" rel="external">
          nedocromil
         </a>
         is not available in any form, and
         <a class="drug drug_pediatric" data-topicid="13184" href="/z/d/drug information/13184.html" rel="external">
          cromolyn
         </a>
         is available only for use in a nebulizer); and sustained-release oral
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         are very rarely used for daily asthma control.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Inhaled glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids are the most effective antiinflammatory agents available for the treatment of asthma. They act by inhibiting most steps in the cascade of the inflammatory response [
         <a href="#rid5">
          5,6
         </a>
         ]. The benefits of glucocorticoids include reduced bronchial hyperresponsiveness, prevention of the late asthmatic response, and enhanced lung function. Inhaled glucocorticoids delivered directly to the airways at a dose much lower than needed when given systemically have minimal side effects. In addition, much of the small amount of drug that is absorbed at low doses is deactivated after one pass through the liver. (See
         <a class="medical medical_review" href="/z/d/html/548.html" rel="external">
          "Molecular effects of inhaled glucocorticoid therapy in asthma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific preparations
         </strong>
         – The inhaled glucocorticoid preparations available in the United States and approved by the US Food and Drug Administration (FDA) for use in children &lt;12 years are listed in the table  (
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         ). Off-label use of inhaled
         <a class="drug drug_pediatric" data-topicid="12996" href="/z/d/drug information/12996.html" rel="external">
          beclomethasone
         </a>
         or inhaled
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         administered by metered dose inhaler (MDI) with spacers or valved holding chamber devices (some will need a facemask) are reasonable alternatives for young children [
         <a href="#rid7">
          7
         </a>
         ]. This table also includes information on potency and dosing. Potency refers to the dose required to achieve the same clinical effect. (See
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Inhaled glucocorticoid treatment is associated with reduction in measures associated with impairment (symptom frequency and severity, functional limitations) and risk (side effects from medications, irreversible decline in lung function, likelihood of asthma exacerbations)  (
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ) [
         <a href="#rid8">
          8-10
         </a>
         ]. Improvements in these parameters are generally greater and occur more frequently than changes seen with LTRAs (
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         ). Efficacy for each indication is discussed below. (See
         <a class="local">
          'Initiating controller therapy'
         </a>
         below and
         <a class="local">
          'Step-up therapy'
         </a>
         below and
         <a class="local">
          'Daily LTRA'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time to improvement
         </strong>
         – A reduction in asthma symptoms may occur rapidly, and reduced inflammation is seen within hours. Lung function continues to improve over four weeks and then plateaus. It may take as long as three months to reach a plateau in response, and any changes in dose should be made at intervals of three months or more [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time to loss of effect after discontinuation
         </strong>
         – When inhaled glucocorticoids are discontinued, there may be a gradual increase in symptoms and airway responsiveness back to pretreatment values. In a study of preschool children, the benefits were only seen while taking inhaled glucocorticoids, with symptoms worsening soon after the inhaled glucocorticoids were stopped [
         <a href="#rid12">
          12
         </a>
         ]. A study of older children also showed that the effects of long-term daily treatment with inhaled glucocorticoids on asthma control and lung function did not persist once these medications were discontinued [
         <a href="#rid13">
          13
         </a>
         ]. Nonetheless, step-down therapy should be attempted at appropriate intervals. (See
         <a class="local">
          'Step-down therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Initial dosing of inhaled glucocorticoids  (
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         ) depends upon the severity of asthma symptoms at the time treatment is initiated  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ). The dose-response curve for the clinical efficacy of inhaled glucocorticoids is relatively flat, with most benefit obtained at the lowest doses used and only small additional benefit attained with higher doses. Long-term control therapy is then stepped up or down at one- to six-month intervals, depending upon clinical response and the ongoing severity of disease. Treatment for acute exacerbations is discussed in detail separately. (See
         <a class="local">
          'Initiating controller therapy'
         </a>
         below and
         <a class="local">
          'Step-up therapy'
         </a>
         below and
         <a class="local">
          'Step-down therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery
         </strong>
         – The mode of delivery for inhaled glucocorticoids greatly influences drug deposition in the lungs and the frequency of local and systemic side effects [
         <a href="#rid14">
          14-16
         </a>
         ]. Delivery systems include MDIs (with or without spacers or valved holding chambers), nebulizers, and dry powder inhalers (DPIs). These delivery systems are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">
          "Delivery of inhaled medication in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">
          "Use of medication nebulizers in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact on disease progression
         </strong>
         – Although inhaled glucocorticoids play a critical role in the chronic management of infants with wheezing and children with asthma, consistent use in childhood does not appear to alter the natural history of asthma once medication is discontinued [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/567.html" rel="external">
          "Natural history of asthma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Airway remodeling, characterized by subepithelial fibrosis, smooth muscle hypertrophy, enlargement of glands, neovascularization, and epithelial alterations, has been noted in endobronchial biopsies from children with severe asthma and is significantly related to bronchodilator responsiveness. However, the evidence that any asthma therapies affect airway remodeling remains uncertain [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A small number of studies have addressed this question [
         <a href="#rid12">
          12,21-25
         </a>
         ]. Three of these studies that enrolled infants and young children who were defined as "at risk" for asthma development and assessed whether the use of inhaled glucocorticoids altered later clinical outcomes found that the early use of inhaled glucocorticoids did not impact the subsequent development of asthma [
         <a href="#rid12">
          12,22,23
         </a>
         ]. A larger study of older children also showed that the effects of long-term daily treatment with inhaled glucocorticoids on asthma control and lung function did not persist once these medications were discontinued [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The effect of chronic inhaled glucocorticoid use in children on adult height appears small.
         <a class="drug drug_pediatric" data-topicid="16842" href="/z/d/drug information/16842.html" rel="external">
          Ciclesonide
         </a>
         appears to have lower systemic absorption and therefore fewer systemic side effects, but a systematic review found no clear benefit-to-harm ratio favoring ciclesonide over
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ]. The potential side effects of inhaled glucocorticoids are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Leukotriene receptor antagonists (LTRAs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         LTRAs are another class of asthma controller medications. Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are potent bronchoconstrictors and also promote production of mucus and proinflammatory cytokines [
         <a href="#rid27">
          27-29
         </a>
         ]. They have been identified in plasma, nasal secretions, sputum, and bronchoalveolar lavage fluid in patients with asthma [
         <a href="#rid30">
          30
         </a>
         ]. Medications that block leukotriene receptors are less effective than inhaled glucocorticoids for treating asthma in most patients. However, some patients have a good response to monotherapy with LTRAs. In addition, results from one randomized trial suggest that, in a minority of patients, LTRAs may be more effective as add-on therapy to inhaled glucocorticoids than adding a LABA or increasing the dose of glucocorticoid [
         <a href="#rid31">
          31,32
         </a>
         ]. Unfortunately, there is no effective way to predict who will respond well to LTRAs. The US FDA has added a boxed warning to the package insert stating that serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         . The efficacy of LTRAs as monotherapy or add-on therapy with inhaled glucocorticoids for persistent asthma is discussed below and in greater detail separately. (See
         <a class="local">
          'Daily LTRA'
         </a>
         below and
         <a class="local">
          'Inhaled glucocorticoid plus LTRA'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/553.html" rel="external">
          "Antileukotriene agents in the management of asthma"
         </a>
         .)
        </p>
        <p>
         Among the LTD4 receptor antagonists,
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         is US FDA approved for control of asthma in children ≥12 months of age, and
         <a class="drug drug_pediatric" data-topicid="12887" href="/z/d/drug information/12887.html" rel="external">
          zafirlukast
         </a>
         is approved for children ≥5 years. Dosing is reviewed in the table  (
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ). Montelukast has an onset of action within one hour. No tachyphylaxis or change in the safety profile has been evidenced after up to 80 weeks of montelukast therapy in pediatric patients aged 6 to 14 years [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Quick-relief use of LTRAs and daily use for exercise-induced asthma are also discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Leukotriene receptor antagonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/533.html" rel="external">
          "Exercise-induced bronchoconstriction", section on 'Prolonged or recurrent exercise'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Long-acting beta agonists (LABAs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         LABAs (
         <a class="drug drug_pediatric" data-topicid="12779" href="/z/d/drug information/12779.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13324" href="/z/d/drug information/13324.html" rel="external">
          formoterol
         </a>
         ), which have a duration of action of at least 12 hours, are used as an adjunct to inhaled glucocorticoids to provide long-term control of asthma symptoms and prevent nocturnal symptoms and exercise-induced bronchoconstriction [
         <a href="#rid34">
          34-38
         </a>
         ]. Monotherapy with LABAs does not treat the inflammatory component of asthma [
         <a href="#rid39">
          39,40
         </a>
         ]. As such, LABAs should not be used as monotherapy. Rather, they should only be used in combination products that contain inhaled glucocorticoids or concomitantly with an inhaled glucocorticoid if no combination product is available. Dosing of combination products is reviewed in the table  (
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ). The onset of action of formoterol is similar to that of
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (three minutes), whereas salmeterol is slower (≥30 minutes).
        </p>
        <p>
         Inhalers containing a LABA, including those using a LABA in combination with an inhaled glucocorticoid, were labeled in the United States from 2010 through 2017 with a boxed warning that advised health care professionals and patients that these agents may increase the chance of severe asthma episodes and asthma-related death when these episodes occur. Subsequent to the placement of this warning, a large (n = 6208), well-conducted trial found no excess of serious asthma events in children receiving a combination inhaler containing both
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         propionate (inhaled glucocorticoid) and
         <a class="drug drug_pediatric" data-topicid="12779" href="/z/d/drug information/12779.html" rel="external">
          salmeterol
         </a>
         (LABA) versus fluticasone alone [
         <a href="#rid41">
          41
         </a>
         ]. A review of this trial and three others prompted the removal of the boxed warning in December 2017 [
         <a href="#rid42">
          42
         </a>
         ]. Long-term use of LABAs in conjunction with inhaled glucocorticoids is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Long-term maintenance therapy with LABAs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2078783012">
         <span class="h2">
          Long-acting anticholinergic agents (LAMAs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          Tiotropium
         </a>
         , an anticholinergic bronchodilator, is approved by the US FDA for long-term maintenance treatment in patients ≥6 years of age with severe symptomatic asthma not well controlled on inhaled glucocorticoids and other maintenance therapies at a dose of 2.5 mcg/day given as two inhalations of 1.25 mcg once daily (the 5 mcg/day dose is an off-label option)  (
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ). Tiotropium should not be used for initial treatment nor as sole therapy for persistent asthma. While either the addition of a LABA or LAMA has been shown to lower the risk of exacerbations and improve lung function over inhaled glucocorticoids alone, triple therapy was not associated with a lower risk of exacerbations [
         <a href="#rid43">
          43
         </a>
         ]. Nonetheless, tiotropium can be added to inhaled glucocorticoids plus a LABA. (See
         <a class="local">
          'Add on tiotropium'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1945576546">
         <span class="h2">
          Biologic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biologic agents for use in children ≥6 years of age with severe asthma  (
         <a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">
          table 6
         </a>
         ) who have not responded to usual therapy include
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         (anti-IgE),
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          dupilumab
         </a>
         (anti-IL-4), and
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          mepolizumab
         </a>
         (anti-IL-5)  (
         <a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-IgE therapy
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          Omalizumab
         </a>
         , a monoclonal antibody against IgE (anti-IgE), is a treatment option for patients with evidence of sensitization to at least one perennial aeroallergen and moderate-to-severe asthma that is not well controlled with standard therapy. Omalizumab is approved for children ≥6 years of age. Dosing is based upon total serum IgE level and weight. Anti-IgE therapy is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy", section on 'Omalizumab therapy in asthma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-IL-4/IL-13 therapy
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          Dupilumab
         </a>
         , a monoclonal antibody against the IL-4 receptor (anti-IL-4R) that inhibits both IL-4 and IL-13 signaling, is approved as add-on maintenance treatment for children ≥6 years of age with moderate-to-severe asthma. Dosing is weight and age based. The dosing for atopic dermatitis should be used if the patient has both atopic dermatitis and asthma. Use in adolescents and adults is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-IL-5 therapy
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          Mepolizumab
         </a>
         , a monoclonal antibody against the IL-5 receptor (anti-IL-5R), is approved as add-on maintenance treatment for children ≥6 years of age with severe eosinophilic asthma [
         <a href="#rid44">
          44
         </a>
         ]. Dosing is 40 mg given subcutaneously every four weeks. Use in adolescents and adults is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Mepolizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3982398928">
         <span class="h1">
          ASSESSING ASTHMA SEVERITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asthma severity is classified based upon current impairment, which includes symptoms; rescue medication use; and, in older children, pulmonary function testing, and future risk of exacerbations that require treatment with systemic glucocorticoids, as outlined in the tables  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ). Assessment of asthma severity before initiating controller therapy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control", section on 'Assessment of severity in patients not on daily therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1998461476">
         <span class="h1">
          INITIATING CONTROLLER THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H1564139265">
         <span class="h2">
          Mild, persistent asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest low-dose, daily inhaled glucocorticoids as initial controller therapy for children with mild, persistent asthma (step 2 therapy)  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2,4,45,46
         </a>
         ]. Alternatives to daily inhaled glucocorticoids for mild, persistent asthma or step 2 therapy include a daily leukotriene receptor antagonist (LTRA) or intermittent low-dose inhaled glucocorticoids taken whenever a short-acting beta agonist (SABA) is used  (
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,3,47
         </a>
         ]. The Global Initiative for Asthma (GINA) guidelines offer two options for adolescents and adults with mild, persistent asthma: as-needed, low-dose inhaled glucocorticoid plus fast-acting long-acting beta agonist (LABA) or inhaled glucocorticoid plus fast-acting LABA as both maintenance and reliever therapy (SMART) [
         <a href="#rid47">
          47
         </a>
         ]. However, further studies are needed in children to determine whether intermittent inhaled glucocorticoids are an effective alternative to daily therapy in at least some patients and to define the optimal threshold at which patients should begin taking daily controller medication. (See
         <a class="medical medical_review" href="/z/d/html/527.html" rel="external">
          "Initiating asthma therapy and monitoring in adolescents and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H79645519">
         <span class="h3">
          Low-dose daily inhaled glucocorticoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy data are primarily extrapolated from adolescent and adult studies since there are only a few trials in children for each inhaled glucocorticoid. These pediatric clinical trials as a whole have demonstrated that daily inhaled glucocorticoids are safe and effective in improving asthma control (symptoms, rescue medication use, and pulmonary function) [
         <a href="#rid21">
          21,41,42,44,45,48-59
         </a>
         ]. However, these studies have several limitations. The trials are relatively small, many are older studies that used as comparators medications that are no longer commonly in use, and they are heterogeneous with regard to age of the patients, disease severity, specific inhaled glucocorticoid studied, comparators used, and outcomes measured.
        </p>
        <p>
         The following studies are illustrative:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Childhood Asthma Management Program (CAMP) trial, 311 children aged 5 to 12 years with mild-to-moderate asthma received
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         (200 mcg twice daily),
         <a class="drug drug_pediatric" data-topicid="12632" href="/z/d/drug information/12632.html" rel="external">
          nedocromil
         </a>
         (a chromone), or placebo [
         <a href="#rid21">
          21
         </a>
         ]. Data from the initial six years of the study demonstrated improved asthma control with fewer hospitalizations (2.5 versus 4.4 per 100 person-years), fewer urgent care visits (12 versus 22 per 100 person-years), fewer courses of
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         for exacerbations (70 versus 122 per 100 person-years), less need for symptomatic treatment with
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         (decreased by 7.4 versus 5.3 puffs per week), and a smaller percentage of days on which additional asthma medications were needed (6.6 versus 18.7 percent) in patients receiving budesonide compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label, controlled trial of children (age one to three years) with recurrent wheezing, 635 children were randomly assigned to receive
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         propionate (100 mcg twice per day) or
         <a class="drug drug_pediatric" data-topicid="13184" href="/z/d/drug information/13184.html" rel="external">
          cromolyn
         </a>
         via metered dose inhaler (MDI) and spacer device for 52 weeks [
         <a href="#rid55">
          55
         </a>
         ]. Compared with those treated with cromolyn, children in the fluticasone group had fewer episodes of severe exacerbation (7 versus 16 percent) and requirements for oral glucocorticoid treatment (6 versus 12 percent), as well as more symptom-free days (odds ratio [OR] 0.5, 95% CI 0.3-0.7) and days without use of rescue treatment (OR 0.6, 95% CI 0.3-0.9).
        </p>
        <p>
        </p>
        <p>
         All inhaled glucocorticoids appear to be equally effective when appropriately dosed [
         <a href="#rid60">
          60
         </a>
         ]. MDIs may be used for any patients, but dry powder inhalers (DPIs) and breath-actuated devices are only appropriate for use in older children who can properly use the devices. Regarding safety,
         <a class="drug drug_pediatric" data-topicid="16842" href="/z/d/drug information/16842.html" rel="external">
          ciclesonide
         </a>
         has less systemic absorption and therefore a lower potential for adverse effects.
        </p>
        <p class="headingAnchor" id="H1670366475">
         <span class="h3">
          Daily LTRA
         </span>
         <span class="headingEndMark">
          —
         </span>
         LTRAs are an alternative to or step-down therapy from inhaled glucocorticoids for mild, persistent asthma, particularly in patients who have difficulty with adherence or inhaler technique [
         <a href="#rid61">
          61
         </a>
         ]. However, use is limited by the risk of neuropsychiatric events, such as suicide, that are associated with this class of drugs. Patients/caregivers should be counseled about these risks. As with inhaled glucocorticoids, much of the efficacy data is extrapolated from adolescent and adult studies. Use of LTRAs for exercise-induced bronchoconstriction is discussed in detail separately. (See
         <a class="local">
          'Leukotriene receptor antagonists (LTRAs)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/553.html" rel="external">
          "Antileukotriene agents in the management of asthma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/533.html" rel="external">
          "Exercise-induced bronchoconstriction", section on 'Prolonged or recurrent exercise'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LTRAs compared with placebo
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          Montelukast
         </a>
         improves asthma symptoms, decreases bronchial hyperreactivity, and decreases the use of beta agonists and systemic glucocorticoids in children aged two to five years with intermittent or persistent asthma [
         <a href="#rid62">
          62-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one multicenter, randomized trial, 689 children aged two to five years were randomly assigned 2:1 to
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         4 mg or placebo for 12 weeks [
         <a href="#rid63">
          63
         </a>
         ]. Modest improvements were noted in daytime (-0.37 versus -0.26 mean change from baseline) and nighttime (-0.46 versus -0.37) asthma symptom scores, percentage of days with asthma symptoms (mean 59 versus 64 percent), and need for rescue medications (used beta agonists 49 versus 55 days and oral glucocorticoids in 19 versus 28 patients) in the treatment group compared with placebo. Montelukast was shown to modestly improve morning forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         )
         <sub>
         </sub>
         compared with placebo in a randomized trial of 336 children aged 6 to 14 years with persistent asthma [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LTRAs compared with inhaled glucocorticoids
         </strong>
         – Several studies in adults and children have shown that inhaled glucocorticoids as initial therapy to control asthma are more effective than leukotriene modifiers for most patients [
         <a href="#rid48">
          48,66-71
         </a>
         ]. A 2010 meta-analysis of randomized trials found that children with mild-to-moderate, persistent asthma who were treated with inhaled glucocorticoids had better pulmonary function and asthma control (eg, fewer asthma exacerbations requiring systemic glucocorticoids, less
         <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">
          albuterol
         </a>
         use, and lower symptom scores) than those treated with
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         [
         <a href="#rid72">
          72
         </a>
         ]. In one study of 342 children (6 to 12 years of age) with persistent asthma randomly assigned to
         <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">
          fluticasone
         </a>
         (50 mcg twice daily) or montelukast (5 mg daily) for 12 weeks, for example, fluticasone significantly increased pulmonary function measurements (11 versus 5 percent increase) and percent of rescue-free days (45 versus 35) and reduced nighttime symptom scores [
         <a href="#rid66">
          66
         </a>
         ]. In another trial, children with greater signs of allergic inflammation and poorer pulmonary function were more likely to respond to fluticasone, whereas younger children with shorter disease duration were more likely to respond to montelukast [
         <a href="#rid71">
          71
         </a>
         ]. In addition, one randomized trial found that fluticasone was more cost effective than montelukast for treatment of mild-to-moderate, persistent asthma in children [
         <a href="#rid73">
          73
         </a>
         ]. These findings support the use of inhaled glucocorticoids as the first-line controller agent  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3877479894">
         <span class="h3">
          Intermittent inhaled glucocorticoid with or without SABA or LABA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asthma treatment guidelines recommend the daily use of inhaled glucocorticoids as first-line controller therapy for all children with persistent asthma  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ) [
         <a href="#rid1">
          1,2,4
         </a>
         ]. However, many patients, particularly those with milder baseline disease, only use inhaled glucocorticoids intermittently, either at the onset of an upper respiratory infection (URI) or at the onset of lower respiratory symptoms. Additionally, many clinicians recommend symptom-based, intermittent therapy for patients with mild, persistent asthma [
         <a href="#rid74">
          74-76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms", section on 'Combination inhaled glucocorticoid and beta agonist'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Based upon the limited data from randomized trials and a meta-analysis, we suggest daily over intermittent use of inhaled glucocorticoids for treatment of persistent asthma in children. If intermittent inhaled glucocorticoids are used and the child fails treatment (ie, requires an unscheduled visit or a course of oral glucocorticoids for asthma), daily therapy should be initiated.
        </p>
        <p>
         There are limited data from randomized trials on preventive use of intermittent inhaled glucocorticoids in children with persistent asthma, and the results are mixed [
         <a href="#rid77">
          77-80
         </a>
         ]. A meta-analysis of randomized trials published through December 2011 that examined intermittent use of inhaled glucocorticoids for persistent asthma in children and adults found no significant difference between intermittent and daily inhaled glucocorticoid therapy with regard to need for rescue oral glucocorticoids or rate of serious adverse health events [
         <a href="#rid81">
          81
         </a>
         ]. In addition, daily therapy was associated with slightly poorer growth in children compared with intermittent therapy. However, daily therapy was superior to intermittent therapy in several other measures, including asthma control, lung function, use of rescue beta agonists, and symptom-free days.
        </p>
        <p>
         The use of intermittent inhaled glucocorticoids in young children with recurrent virus-induced wheezing is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/546.html" rel="external">
          "Treatment of recurrent virus-induced wheezing in young children", section on 'Intermittent preventive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4019780913">
         <span class="h3">
          Intermittent LTRA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that intermittent use of leukotriene receptor antagonists (LTRAs) is
         <strong>
          not
         </strong>
         effective in preventing the development of asthma symptoms.
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          Montelukast
         </a>
         was not effective in preventing the seasonal increase in asthma symptoms, rescue medication use (beta agonists and oral glucocorticoids), and unanticipated health care visits when initiated at the start of the school year in a randomized trial of 1162 children aged 6 to 14 years with asthma of any severity [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H906729235">
         <span class="h2">
          Moderate-to-severe, persistent asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest low-dose inhaled glucocorticoid in combination with a LABA as initial controller therapy for children with moderate, persistent asthma (step 3 therapy)  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ). The alternatives are medium-dose inhaled glucocorticoids or low-dose inhaled glucocorticoids plus an LTRA. For initial therapy in children with severe, persistent asthma, we suggest medium-dose inhaled glucocorticoids in combination with a LABA (step 4 therapy). The alternatives are medium-dose inhaled glucocorticoids plus a LTRA or, in children ≥5 years of age, high-dose inhaled glucocorticoids or medium-dose inhaled glucocorticoid-LABA plus
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         or LTRA.
        </p>
        <p>
         Children who are started on controller therapy at the time of an acute exacerbation or who have moderate-to-severe disease and are at high risk for an exacerbation may also require a short course of oral glucocorticoids. Inhaled glucocorticoids are not sufficient for the management of asthma exacerbations [
         <a href="#rid83">
          83
         </a>
         ]. The use of inhaled and systemic glucocorticoids as rescue agents for asthma exacerbations is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Systemic glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1368099115">
         <span class="h3">
          Inhaled glucocorticoid plus LABA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies in adolescents and adults indicate that long-acting inhaled beta agonists (LABAs;
         <a class="drug drug_pediatric" data-topicid="12779" href="/z/d/drug information/12779.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13324" href="/z/d/drug information/13324.html" rel="external">
          formoterol
         </a>
         ) have the potential to improve overall asthma control when added to inhaled glucocorticoids in patients who are inadequately controlled with inhaled glucocorticoids alone  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid84">
          84-91
         </a>
         ]. Formoterol is fast onset, whereas salmeterol is slower onset. The use of combined therapy is associated with better linear growth [
         <a href="#rid92">
          92
         </a>
         ], but higher doses of inhaled glucocorticoid monotherapy appear to better control lung inflammation [
         <a href="#rid68">
          68
         </a>
         ]. A systematic review and meta-analysis of 33 trials in 6381 children found that the addition of LABAs was associated with greater improvement in lung function and reduced use of rescue inhalers compared with a baseline or increased dose of inhaled glucocorticoids but did not appear to have a greater effect on other measures of asthma control, such as number of exacerbations requiring treatment with oral glucocorticoids or hospital admissions [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Long-term maintenance therapy with LABAs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p>
         LABAs should always be used in combination with an inhaled glucocorticoid because of safety concerns regarding the use of LABAs alone [
         <a href="#rid93">
          93
         </a>
         ]. A large clinical trial has provided reassurance about the safety of combination inhaled glucocorticoids and LABAs in children [
         <a href="#rid41">
          41,94
         </a>
         ]. The potential safety issues surrounding long-term use of LABAs are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Evidence of LABA-ICS safety'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929232956">
         <span class="h3">
          Medium-dose inhaled glucocorticoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy data are primarily extrapolated from adolescent and adult studies, with limited studies performed in children [
         <a href="#rid31">
          31,95
         </a>
         ]. Typically, patients respond better to the addition of a LABA rather than an increase in the dose of the inhaled glucocorticoid. However, some children, particularly those of African American heritage, may respond better to a higher dose of inhaled glucocorticoid. Thus, if one approach is tried and is unsuccessful in attaining asthma control, an alternative should be chosen. (See
         <a class="local">
          'Low-dose daily inhaled glucocorticoid'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/532.html" rel="external">
          "Ongoing monitoring and titration of asthma therapies in adolescents and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2096512252">
         <span class="h3">
          Inhaled glucocorticoid plus LTRA
         </span>
         <span class="headingEndMark">
          —
         </span>
         In randomized trials in children between the ages of 6 and 14 years receiving inhaled glucocorticoids for asthma, a greater improvement in morning FEV
         <sub>
          1
         </sub>
         and decreased need for rescue use of SABAs were seen with the addition of
         <a class="drug drug_pediatric" data-topicid="12620" href="/z/d/drug information/12620.html" rel="external">
          montelukast
         </a>
         compared with the addition of
         <a class="drug drug_pediatric" data-topicid="13184" href="/z/d/drug information/13184.html" rel="external">
          cromolyn
         </a>
         or placebo [
         <a href="#rid65">
          65,96,97
         </a>
         ]. However, increasing the dose of inhaled glucocorticoids may provide better protection from exacerbations and need for systemic glucocorticoids compared with the combination of montelukast and low-dose inhaled glucocorticoids [
         <a href="#rid32">
          32
         </a>
         ]. This was illustrated in a trial in which 71 children, aged 6 to 14 years, were randomly assigned to combined therapy with montelukast (5 mg daily) plus
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         (100 mcg twice daily) or budesonide (200 mcg twice daily) for 12 weeks [
         <a href="#rid98">
          98
         </a>
         ]. The two therapies resulted in similar lung function parameters and weekly asthma symptom scores, although more children in the group receiving combined therapy had acute exacerbations (33 versus 9 percent) and these exacerbations were more severe. An additional concern is the adherence to taking two separate medications rather than one (inhaled glucocorticoid alone or inhaled glucocorticoid plus LABA) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2662257591">
         <span class="h2">
          Patient/caregiver education
         </span>
         <span class="headingEndMark">
          —
         </span>
         The child and caregivers should receive instruction regarding the proper use of the medication delivery system(s) prescribed to ensure that the child receives the full benefit of the medication(s). Potential side effects should also be discussed with the child's caregivers. (See
         <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">
          "Use of medication nebulizers in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/553.html" rel="external">
          "Antileukotriene agents in the management of asthma", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H224574915">
         <span class="h1">
          ASSESSING ASTHMA CONTROL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asthma control is periodically assessed in patients with established asthma on therapy. It is defined as the extent to which therapy reduces or eliminates the manifestations of asthma. In addition to assessing the components of current impairment and future risk, it also includes evaluation for medication side effects. Assessment of control is reviewed in the tables and discussed in greater detail separately  (
         <a class="graphic graphic_table graphicRef64986 graphicRef78322" href="/z/d/graphic/64986.html" rel="external">
          table 4A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control", section on 'Assessment of control'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H388150032">
         <span class="h1">
          STEP-UP THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Step-up therapy is recommended if asthma control  (
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ) is not achieved with the proper and consistent use of the prescribed medications. Proper technique for medication administration and adequate adherence should be confirmed before stepping up therapy. Patients who are not well controlled on their current regimen are usually stepped up one step. Patients who are very poorly controlled may be stepped up two steps rather than one. Some patients with very poorly controlled asthma may also require a short course of oral glucocorticoids to attain asthma control. Patients should be reassessed in four to six weeks. For patients who do not respond to one step-up therapy, another at that step level may be tried before moving up a step unless the patient is very poorly controlled. Monitoring asthma control and determining need for step-up therapy are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1993902485">
         <span class="h2">
          Step-up therapy for mild-to-moderate asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Step-up therapy for mild-to-moderate asthma involves increasing the inhaled glucocorticoid dose and/or adding a long-acting beta agonist (LABA) or leukotriene receptor antagonist (LTRA)  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who were started on an alternative to inhaled glucocorticoids as initial therapy for mild, persistent asthma (step 2) and failed, we suggest low-dose inhaled glucocorticoids alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are not well controlled on low-dose inhaled glucocorticoids as initial therapy, we suggest stepping up their therapy by adding a LABA (step 3)  (
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,31,100
         </a>
         ]. Reasonable alternatives are to add an LTRA to low-dose inhaled glucocorticoids or increase inhaled glucocorticoids to a moderate dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The preferred step up for patients who are not well controlled on step 3 therapy is a medium-dose inhaled glucocorticoid combined with a LABA (step 4) since the risk of side effects increases with the inhaled glucocorticoid dose. A reasonable alternative is to add an LTRA. For patients who do not respond to the preferred step 4 therapies, the option is high-dose inhaled glucocorticoids alone. (See
         <a class="local">
          'Inhaled glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         In a systematic review and meta-analysis, outcomes were similar for low-dose inhaled glucocorticoid plus LABA and moderate-dose inhaled glucocorticoids with regard to risk of exacerbations requiring oral glucocorticoids and risk of hospital admission, but better improvement in lung function was seen in patients on a LABA [
         <a href="#rid92">
          92
         </a>
         ]. However, data from a trial in 280 Black children aged 5 to 11 years who were not well controlled on low-dose inhaled glucocorticoids showed that almost half responded better to high-dose inhaled glucocorticoids, whereas the other nearly half of patients responded better to moderate-dose inhaled glucocorticoids plus a LABA [
         <a href="#rid95">
          95
         </a>
         ]. Thus, if any patient is not well controlled after the first option is tried, the alternative approach should be taken.
        </p>
        <p>
         Use of inhaled glucocorticoids combined with a LABA is not recommended for acute exacerbations in children who are not on maintenance controller therapy or are on inhaled glucocorticoid monotherapy. However, one randomized trial using combination therapy (inhaled glucocorticoid plus a fast-acting LABA,
         <a class="drug drug_pediatric" data-topicid="12959" href="/z/d/drug information/12959.html" rel="external">
          budesonide-formoterol
         </a>
         ) for both maintenance and rescue therapy, compared with combination therapy or inhaled glucocorticoid for maintenance and a short-acting beta agonist (SABA;
         <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">
          terbutaline
         </a>
         ) for rescue therapy, found a lower rate of exacerbations in the first group [
         <a href="#rid101">
          101
         </a>
         ]. This study suggests that as-needed use of combination therapy in conjunction with maintenance combination therapy is beneficial in children with moderate asthma that is not well controlled.
        </p>
        <p class="headingAnchor" id="H479970364">
         <span class="h2">
          Step-up therapy for severe asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children less than six years of age, the preferred approach is to increase to high-dose inhaled glucocorticoids in combination with a LABA, or alternatively an LTRA (step 5). Additional agents are available for children ≥6 years of age who have moderate-to-severe asthma that is difficult to control  (
         <a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          Tiotropium
         </a>
         , a long-acting anticholinergic agent, is approved for long-term maintenance treatment in children with severe symptomatic asthma not well controlled on inhaled glucocorticoids and other maintenance therapies (LABAs and/or LTRAs) [
         <a href="#rid103">
          103,104
         </a>
         ]. (See
         <a class="local">
          'Long-acting anticholinergic agents (LAMAs)'
         </a>
         above.)
        </p>
        <p>
         For children six years of age and older whose asthma is still not controlled after the addition of
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         , addition of a biologic agent is another option. Monoclonal anti-IgE therapy with
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         is appropriate for children with poorly controlled, moderate-to-severe, persistent asthma; sensitization to at least one perennial aeroallergen; and elevated serum IgE [
         <a href="#rid105">
          105
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          Mepolizumab
         </a>
         , a monoclonal antibody against interleukin 5 (anti-IL-5), is approved as add-on maintenance treatment for children with poorly controlled severe eosinophilic asthma (eosinophilic phenotype is typically determined by blood eosinophil count, but some use fractional exhaled nitric oxide [FeNO] values or sputum eosinophil proportions) [
         <a href="#rid44">
          44
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          Dupilumab
         </a>
         , a monoclonal antibody against the IL-4 receptor alpha subunit, is also approved for treatment of moderate-to-severe, eosinophilic asthma [
         <a href="#rid106">
          106
         </a>
         ]. Use of other biologic agents for asthma is off label in children &lt;12 years of age. (See
         <a class="local">
          'Biologic agents'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy", section on 'Omalizumab therapy in asthma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Persistently uncontrolled asthma'
         </a>
         .)
        </p>
        <p>
         Systemic glucocorticoids are most commonly used for management of acute exacerbations. They are used rarely for long-term control in children with severe, persistent asthma (step 6), particularly with the availability of
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         and the biologic agents  (
         <a class="graphic graphic_table graphicRef127785" href="/z/d/graphic/127785.html" rel="external">
          table 5A
         </a>
         and
         <a class="graphic graphic_table graphicRef127786" href="/z/d/graphic/127786.html" rel="external">
          table 5B
         </a>
         and
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,2,4
         </a>
         ]. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3418338764">
         <span class="h3">
          Add on tiotropium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accumulating data suggest that
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         added on to inhaled glucocorticoids plus one or more additional controller medications improves asthma control and decreases the rate of exacerbations in children 6 to 11 years old with moderate-to-severe symptomatic asthma [
         <a href="#rid107">
          107
         </a>
         ]. In a 12-week randomized trial with 401 participants aged 6 to 11 years, once-daily tiotropium 5 mcg, but not the 2.5 mcg dose, improved lung function and was well tolerated as add-on therapy to inhaled glucocorticoids and other maintenance therapies in children with severe symptomatic asthma [
         <a href="#rid103">
          103
         </a>
         ]. However, consistent with studies in adults, no differences were noted in patient-important outcomes such as asthma symptoms and rescue medication use. A case series also reported benefit from the addition of tiotropium in patients not well controlled on inhaled glucocorticoids and LABAs [
         <a href="#rid104">
          104
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Inhaled GC/LAMA or GC/LAMA/LABA'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1461838337">
         <span class="h3">
          Add on a biologic agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         The biologic agents,
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         (anti-IgE),
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          mepolizumab
         </a>
         (anti-IL-5), and
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          dupilumab
         </a>
         (anti-IL-4 and IL-13), are usually reserved for children six years of age and older who have not responded to the addition of
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         .
        </p>
        <p>
         Treatment with
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         (compared with placebo) can decrease incidence of exacerbations and result in a significant reduction in the dose of inhaled or oral glucocorticoids required to control symptoms. Omalizumab (anti-IgE) has never been compared directly with other asthma therapies in controlled clinical trials. The efficacy of omalizumab is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy", section on 'Omalizumab therapy in asthma'
         </a>
         .)
        </p>
        <p>
         Approval of
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          mepolizumab
         </a>
         (anti-IL-5) was primarily based upon trials in adolescents and adults as well as pharmacodynamic, pharmacokinetic, and safety data in a small number of children 6 to 11 years of age [
         <a href="#rid108">
          108,109
         </a>
         ]. A subsequent trial of mepolizumab in 290 children and adolescents from low-resource, urban environments with eosinophilic asthma and ≥2 exacerbations/year showed a lesser benefit from mepolizumab on asthma exacerbations compared with studies in adults (0.96 exacerbations per year with mepolizumab versus 1.3 per year with placebo [RR 0.73, 95% CI 0.56-0.96] [
         <a href="#rid110">
          110
         </a>
         ] compared with a RR of 0.49 in a systematic review of adult studies [
         <a href="#rid111">
          111
         </a>
         ]), and no difference was seen with other outcomes. Persistent airway mucus hypersecretion and increased expression of non-type 2 inflammatory pathways were noted in the mepolizumab-treated group, which may explain, in part, the differential response to mepolizumab. Other factors may include ongoing environmental exposures, other asthma mechanisms, biologic changes between childhood and adult asthma, or other differences in the overall study populations. The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in adolescents and adults, as were exploratory efficacy data showing improved asthma control and decreased exacerbation rates [
         <a href="#rid109">
          109
         </a>
         ]. Efficacy data in adolescents and adults are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Mepolizumab'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          Dupilumab
         </a>
         (anti-IL-4 and IL-13) was approved by the US Food and Drug Administration (FDA) in 2021 as add-on maintenance treatment for children six years of age and older with moderate-to-severe persistent asthma who have an eosinophilic phenotype or who are dependent on oral glucocorticoids [
         <a href="#rid112">
          112
         </a>
         ]. Approval was primarily based upon trials in adolescents and adults as well as efficacy and safety data from a single randomized trial for moderate-to-severe persistent asthma in 408 children 6 to 11 years of age that showed an improvement in lung function and asthma control and a significant reduction in the annual rate of severe exacerbations requiring treatment with systemic glucocorticoids (0.31, 95% CI 0.22-0.42 on dupilumab versus 0.75, 95% CI 0.54-1.03 for placebo; relative risk reduction in dupilumab group 59.3%, 95% CI 39.5-72.6) [
         <a href="#rid113">
          113
         </a>
         ]. Additional safety data were derived from an atopic dermatitis trial in children. Dosing is 100 mg subcutaneous every other week or 300 mg every four weeks for patients 15 to &lt;30 kg and 200 mg every other week for children 6 to 11 years of age who are ≥30 kg. Patients who also have moderate-to-severe atopic dermatitis (AD) should follow dosing for AD. Efficacy and safety data for asthma treatment in adolescents and adults and for atopic dermatitis treatment in children are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1726.html" rel="external">
          "Management of severe atopic dermatitis (eczema) in children", section on 'Dupilumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H249858666">
         <span class="h1">
          STEP-DOWN THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decreasing or stepping down therapy is considered once asthma control is attained for at least three months  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ). The medication options and approaches are similar to initial therapy and step-up therapy. Monitoring asthma control and determining when a patient is ready for step-down therapy are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3610378844">
         <span class="h1">
          MINIMIZING ADVERSE EFFECTS OF INHALED GLUCOCORTICOIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         To minimize the risk of adverse effects of inhaled glucocorticoids in children, we advise the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Step down treatment to the lowest possible dose of inhaled glucocorticoids that maintains symptom control  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use metered dose inhalers (MDIs) with a spacer. A valved holding chamber is preferred because this type of spacer has an exhalation valve that prevents the patient from breathing back into the spacer and changing the character of the medication/vehicle, making it less effective. Children ≤6 years of age should use a facemask with the valved holding chamber. (See
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children", section on 'Spacers and holding chambers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluate and treat for conditions which may exacerbate asthma (eg, allergic rhinitis, sinusitis, or gastroesophageal reflux)  (
         <a class="graphic graphic_table graphicRef80507" href="/z/d/graphic/80507.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5742.html" rel="external">
          "Asthma in children younger than 12 years: Initial evaluation and diagnosis", section on 'Precipitating factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximize nonpharmacologic treatment (eg, trigger avoidance). (See
         <a class="medical medical_review" href="/z/d/html/562.html" rel="external">
          "Trigger control to enhance asthma management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Adverse effects of inhaled glucocorticoids appear to be rare and are dose related; they are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H131909321">
         <span class="h1">
          ADVICE RELATED TO COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention (CDC) have identified asthma as a risk factor for severe coronavirus disease 2019 (COVID-19; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) [
         <a href="#rid114">
          114
         </a>
         ], although supporting evidence remains mixed, with data largely from studies in adults [
         <a href="#rid115">
          115-126
         </a>
         ]. Several studies that included patients with well-controlled asthma did not indicate increased risk in this population [
         <a href="#rid115">
          115-122
         </a>
         ]. In addition, contrary to that expected for a viral respiratory infection, initial data suggested that COVID-19 did not increase asthma morbidity in children [
         <a href="#rid127">
          127-130
         </a>
         ]. However, other investigations of COVID-19 outcomes have reported increased risk, including a large meta-analysis of over 100,000 patients that reported higher rates of intubation and prolonged mechanical ventilation in adults with asthma [
         <a href="#rid116">
          116,123-125
         </a>
         ]. A comparison of nearly 62,000 children with asthma from 108 health care systems in the United States from March 2020 through February 2021 found that a SARS-CoV-2 polymerase chain reaction (PCR) positive test was associated with increased rates of emergency department visits, hospitalizations, and use of short-acting beta agonists (SABAs) and oral glucocorticoids in the six months following the positive test compared with those who tested negative [
         <a href="#rid126">
          126
         </a>
         ]. These complications probably occur more frequently in those with poorly controlled asthma at baseline. Thus, patients with asthma should continue all regular medications necessary to maintain optimal asthma control, including inhaled glucocorticoids, oral glucocorticoids, and/or biologic agents (
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          dupilumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          mepolizumab
         </a>
         ) [
         <a href="#rid131">
          131-133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">
          "COVID-19: Clinical manifestations and diagnosis in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">
          "COVID-19: Management in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3266485018">
         <span class="h1">
          INFREQUENTLY USED TREATMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Daily controller medications that are used rarely for persistent asthma include systemic (oral) glucocorticoids, chromones (
         <a class="drug drug_pediatric" data-topicid="13184" href="/z/d/drug information/13184.html" rel="external">
          cromolyn
         </a>
         sodium and
         <a class="drug drug_pediatric" data-topicid="12632" href="/z/d/drug information/12632.html" rel="external">
          nedocromil
         </a>
         ), and
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2771104217">
         <span class="h2">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although oral glucocorticoids improve asthma control, the adverse effects of their long-term use must be appreciated. These include adrenal suppression, weight gain, diabetes, hypertension, cataracts, delayed growth, immune suppression, osteoporosis, and psychologic effects [
         <a href="#rid6">
          6,134
         </a>
         ]. Reducing glucocorticoids to the lowest possible dose, administering them every other day, and maximizing all other forms of pharmacologic and preventive therapy minimize these effects. A strategy of substituting inhaled glucocorticoids has generally been successful in older children and adults, as well as in infants [
         <a href="#rid135">
          135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
         The use of systemic glucocorticoids as rescue agents for asthma exacerbations is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management", section on 'Management of inflammation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Systemic glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2834093662">
         <span class="h2">
          Chromones
         </span>
         <span class="headingEndMark">
          —
         </span>
         The drugs
         <a class="drug drug_pediatric" data-topicid="13184" href="/z/d/drug information/13184.html" rel="external">
          cromolyn
         </a>
         sodium and
         <a class="drug drug_pediatric" data-topicid="12632" href="/z/d/drug information/12632.html" rel="external">
          nedocromil
         </a>
         are commonly grouped together as chromones (also called cromoglycates). These drugs have mast cell-stabilizing properties and appear to diminish the very early stages of an asthmatic response to external triggers. However, their efficacy as controller medications in childhood asthma has not been definitively established [
         <a href="#rid136">
          136,137
         </a>
         ]. Although there are studies in which cromolyn compared favorably with other established therapies, a systematic review of trials of cromolyn versus placebo found no clear therapeutic effect [
         <a href="#rid138">
          138-141
         </a>
         ]. In addition, a meta-analysis found that inhaled glucocorticoids were superior to cromolyn as controller therapy for mild, persistent asthma in children, with improved pulmonary function, fewer exacerbations, lower asthma symptom scores, and less bronchodilator use [
         <a href="#rid142">
          142
         </a>
         ]. Like cromolyn, nedocromil appears to be less effective than inhaled glucocorticoids in controlling asthma [
         <a href="#rid21">
          21,143-146
         </a>
         ].
        </p>
        <p>
         There is no definitive evidence to support the concurrent use of inhaled chromones and glucocorticoids in order to lower the glucocorticoid dose in patients with chronic asthma. The disadvantages of high cost and multiple daily dosing probably outweigh the unproven potential benefit, and concurrent use is not recommended.
        </p>
        <p class="headingAnchor" id="H3075227037">
         <span class="h2">
          Theophylline
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          Theophylline
         </a>
         is a medication with both bronchodilatory and antiinflammatory properties. It may also have steroid-sparing and immunomodulatory effects [
         <a href="#rid147">
          147-149
         </a>
         ]. However, the role of theophylline in the stepwise management of childhood asthma has declined worldwide.
        </p>
        <p>
         The use of
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         to treat chronic childhood asthma is problematic due to potentially serious short-term side effects (eg, cardiac arrhythmias, seizures, death) and long-term adverse effects (learning and behavior disorders). A further encumbrance of theophylline is the need for frequent serum monitoring to maintain a serum concentration of 5 to 15 mcg/mL, as well as vigilance regarding potential interactions with other drugs. The use of theophylline is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/560.html" rel="external">
          "Theophylline use in asthma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3919344131">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113453.html" rel="external">
          "Society guideline links: Asthma in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16116.html" rel="external">
          "Patient education: How to use your child's dry powder inhaler (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15344.html" rel="external">
          "Patient education: Asthma in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16115.html" rel="external">
          "Patient education: How to use your child's metered dose inhaler (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1173.html" rel="external">
          "Patient education: Asthma inhaler techniques in children (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1172.html" rel="external">
          "Patient education: Asthma treatment in children (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1222.html" rel="external">
          "Patient education: Asthma symptoms and diagnosis in children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment goals
         </strong>
         – The overarching goals are to maintain control of asthma symptoms and reduce exacerbations with the least amount of medication and side effects. (See
         <a class="local">
          'Goals of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity assessment
         </strong>
         – Asthma severity is classified based upon current impairment, which includes symptoms; quick-relief medication use; and, in older children, pulmonary function testing, and future risk of exacerbations that require treatment with systemic glucocorticoids, as outlined in the tables  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ). (See
         <a class="local">
          'Assessing asthma severity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiating controller therapy
         </strong>
         – Our general approach to initiating controller therapy is as follows  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ) (see
         <a class="local">
          'Initiating controller therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild, persistent asthma
         </strong>
         – For children &lt;12 years of age with mild, persistent asthma, we suggest low-dose inhaled glucocorticoids  (
         <a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">
          table 1
         </a>
         ) for initial controller therapy (step 2 therapy) rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Reasonable alternatives are a daily leukotriene receptor antagonist (LTRA) or intermittent, low-dose inhaled glucocorticoids used whenever short-acting beta agonist (SABA) quick-relief therapy is used  (
         <a class="graphic graphic_table graphicRef57761" href="/z/d/graphic/57761.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Mild, persistent asthma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate, persistent asthma
         </strong>
         – For children &lt;4 years of age with moderate, persistent asthma, we suggest a low-dose inhaled glucocorticoid in combination with a long-acting beta agonist (LABA) or an LTRA as initial controller therapy (step 3 therapy) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A reasonable alternative is medium-dose inhaled glucocorticoids. (See
         <a class="local">
          'Moderate-to-severe, persistent asthma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children 5 to 11 years of age with moderate, persistent asthma, we suggest low-dose inhaled glucocorticoid in combination with a fast-onset LABA rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This combination inhaler can also be used for relief of acute symptoms. Reasonable alternatives include a low-dose inhaled glucocorticoid in combination with a slower-onset LABA, medium-dose inhaled glucocorticoids, or low-dose inhaled glucocorticoids plus an LTRA. (See
         <a class="local">
          'Moderate-to-severe, persistent asthma'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">
          "Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms", section on 'Combination inhaled glucocorticoid and beta agonist'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe, persistent asthma
         </strong>
         – For initial therapy in children with severe, persistent asthma, we suggest medium-dose inhaled glucocorticoids in combination with a LABA (step 4 therapy) rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A fast-onset LABA is preferred in children ≥4 years of age. Reasonable alternatives include medium-dose inhaled glucocorticoids plus a LTRA or, in children ≥5 years of age, high-dose inhaled glucocorticoids or medium-dose inhaled glucocorticoid-LABA plus
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         . (See
         <a class="local">
          'Moderate-to-severe, persistent asthma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patient/caregiver education
         </strong>
         – When inhaled glucocorticoids are prescribed, it is essential to provide adequate instruction to the child's caregivers regarding proper use of the medication delivery system. Potential side effects of all medications should also be discussed with the child's caregivers. (See
         <a class="local">
          'Patient/caregiver education'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">
          "Use of medication nebulizers in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">
          "The use of inhaler devices in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/553.html" rel="external">
          "Antileukotriene agents in the management of asthma", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/558.html" rel="external">
          "Beta agonists in asthma: Acute administration and prophylactic use", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjusting therapy
         </strong>
         – Asthma control should be monitored regularly  (
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ) and controller therapy adjusted as necessary  (
         <a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">
          table 5A-B
         </a>
         ). The minimum effective medication regimen for each patient should be determined. However, this can change over time. (See
         <a class="local">
          'Assessing asthma control'
         </a>
         above and
         <a class="local">
          'Step-up therapy'
         </a>
         above and
         <a class="local">
          'Step-down therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control", section on 'Monitoring and dosing adjustment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Step-up therapy
         </strong>
         – If asthma control  (
         <a class="graphic graphic_table graphicRef78322 graphicRef64986" href="/z/d/graphic/78322.html" rel="external">
          table 4A-B
         </a>
         ) is not achieved with the proper and consistent use of the prescribed medications, step-up therapy is appropriate. Proper technique and adequate adherence should be confirmed before stepping up therapy. (See
         <a class="local">
          'Step-up therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Not-well-controlled asthma
         </strong>
         – Patients who are not well controlled on their current regimen are usually stepped up one step. One exception is patients who failed intermittent inhaled glucocorticoids for step 2 therapy. For those patients, we suggest switching to daily low-dose inhaled glucocorticoids rather than moving up to step 3 therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Patients should be reassessed in four to six weeks. For patients who do not respond to one step-up therapy, another at that step level may be tried before moving up a step unless the patient is very poorly controlled.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Poorly controlled asthma
         </strong>
         – Patients who are very poorly controlled may be stepped up two steps rather than one. Some patients with very poorly controlled asthma may also require a short course of oral glucocorticoids to attain asthma control.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe asthma
         </strong>
         – For children ≤5 years of age with severe asthma that is not controlled on preferred step 4 therapy, we suggest high-dose inhaled glucocorticoid in combination with a LABA (step 5) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A reasonable alternative is high-dose inhaled glucocorticoid plus an LTRA.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For children 6 to 11 years of age with severe asthma that is not controlled on step 4 therapy, we suggest adding the long-acting anticholinergic agent,
         <a class="drug drug_pediatric" data-topicid="12953" href="/z/d/drug information/12953.html" rel="external">
          tiotropium
         </a>
         (step 5) rather than other add-on therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Reasonable alternatives are a combination of medium-dose inhaled glucocorticoid plus both LABA and LTRA or high-dose inhaled glucocorticoids in addition to a LABA or LTRA. The biologic agents,
         <a class="drug drug_pediatric" data-topicid="12905" href="/z/d/drug information/12905.html" rel="external">
          omalizumab
         </a>
         (anti-immunoglobulin E [IgE]),
         <a class="drug drug_pediatric" data-topicid="108766" href="/z/d/drug information/108766.html" rel="external">
          mepolizumab
         </a>
         (anti-interleukin [IL] 5), and
         <a class="drug drug_pediatric" data-topicid="120255" href="/z/d/drug information/120255.html" rel="external">
          dupilumab
         </a>
         (anti-IL-4 and IL-13), are usually reserved for children six years of age and older who have not responded to the addition of tiotropium. (See
         <a class="local">
          'Long-acting anticholinergic agents (LAMAs)'
         </a>
         above and
         <a class="local">
          'Biologic agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Longer-term use of oral glucocorticoids is reserved for step 6 therapy when all other therapy has failed because of the significant adverse effects associated with this treatment. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Step-down therapy
         </strong>
         – Decreasing or stepping down therapy is considered once asthma control is attained for at least three months. The medication options and approaches are similar to initial therapy and step-up therapy. (See
         <a class="local">
          'Step-down therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3). 2012. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on August 31, 2021).
         </li>
         <li class="breakAll">
          2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines (Accessed on January 25, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J 2012; 19:127.
          </a>
         </li>
         <li class="breakAll">
          Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: Updated 2020. https://www.ginasthma.org (Accessed on November 30, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen GL. Asthma in children. N Engl J Med 1992; 326:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991; 88:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaqundah PY, Sugerman RW, Ceruti E, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr 2006; 149:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics 2009; 123:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009; 123:e519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes PJ. Inhaled Corticosteroids. Pharmaceuticals (Basel) 2010; 3:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strunk RC, Sternberg AL, Szefler SJ, et al. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009; 154:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson DS, Geddes DM. Inhaled corticosteroids: benefits and risks. J Asthma 1996; 33:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FD. Managing childhood asthma: challenge of preventing exacerbations. Pediatrics 2009; 123 Suppl 3:S146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 2010; 17:e85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron C, Al-Ramli W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc 2009; 6:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Sjoukes A, Richards D, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 2011; 184:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childhood Asthma Management Program Research Group, Szefler S, Weiss S, et al. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lødrup Carlsen KC, Devulapalli CS, Mowinckel P, et al. Lung function at 10 yrs is not improved by early corticosteroid treatment in asthmatic children. Pediatr Allergy Immunol 2010; 21:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer S, Rottier BL, Scholten RJ, Boluyt N. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2013; :CD010352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17:22S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachelefsky G. Childhood asthma and allergic rhinitis: the role of leukotrienes. J Pediatr 1997; 131:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev 2013; :CD009585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scaparrotta A, Di Pillo S, Attanasi M, et al. Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med 2012; 7:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989; 84:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronsky EA, Pearlman DS, Pobiner BF, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices. Pediatrics 1999; 104:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blake K, Pearlman DS, Scott C, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Ann Allergy Asthma Immunol 1999; 82:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nino G, Grunstein MM. Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma. Curr Opin Pediatr 2010; 22:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stempel DA, Szefler SJ, Pedersen S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med 2016; 375:840.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS) https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=Long-Acting%20Beta%20agonists%20%28LABAs%29%20and%20Inhaled%20Corticosteroids%20%28ICS%29&amp;utm_medium=email&amp;utm_source=Eloqua&amp;elqTrackId=de90a40b47ac46f49cbfedb9752d9a88&amp;elq=62c18bc18584487f8d6f06c9c1554121&amp;elqaid=1864&amp;elqat=1&amp;elqCampaig (Accessed on December 21, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobieraj DM, Baker WL, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. JAMA 2018; 319:1473.
          </a>
         </li>
         <li class="breakAll">
          Mepolizumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125526s012,761122s002s003lbl.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr 2008; 167:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; :CD002314.
          </a>
         </li>
         <li class="breakAll">
          Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004; :CD002314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child 1992; 67:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child 1993; 69:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H, Munck SL, Nielsen JP, et al. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet 1990; 336:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleeson JG, Price JF. Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. BMJ 1988; 297:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H, Allen DB, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113:e87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peden DB, Berger WE, Noonan MJ, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol 1998; 102:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Aalderen WM, Grigg J, Guilbert TW, et al. Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma. J Allergy Clin Immunol Pract 2015; 3:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noonan M, Leflein J, Corren J, Staudinger H. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. BMC Pediatr 2009; 9:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postma DS, Dekhuijzen R, van der Molen T, et al. Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids. Allergy Asthma Immunol Res 2017; 9:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Axelsson I, Naumburg E, Prietsch SO, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev 2019; 6:CD010126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moeller A, Lehmann A, Knauer N, et al. Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children. Pediatr Pulmonol 2008; 43:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakim F, Vilozni D, Adler A, et al. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007; 131:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child 2010; 95:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Hollenbeak CS, Mauger DT, et al. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2011; 127:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraft M, Israel E, O'Connor GT. Clinical Decisions. Treatment of mild persistent asthma. N Engl J Med 2007; 356:2096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawicki GS, Smith L, Bokhour B, et al. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Clin Pediatr (Phila) 2008; 47:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naspitz CK, Cropp GJ. Recommendations for treatment of intermittent mild persistent asthma in children and adolescents. Pediatr Pulmonol 2009; 44:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiger RS, Mauger D, Bacharier LB, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365:1990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svedmyr J, Nyberg E, Asbrink-Nilsson E, Hedlin G. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Acta Paediatr 1995; 84:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013; :CD009611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss KB, Gern JE, Johnston NW, et al. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann Allergy Asthma Immunol 2010; 105:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossny E, Rosario N, Lee BW, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J 2016; 9:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan RA, Pinnas JL, Schwartz HJ, et al. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Ann Allergy Asthma Immunol 1999; 82:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997; 52:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilding P, Clark M, Thompson Coon J, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gappa M, Zachgo W, von Berg A, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009; 44:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2015; :CD007949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2012; 10:CD010005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush A, Frey U. Safety of Long-Acting Beta-Agonists in Children with Asthma. N Engl J Med 2016; 375:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechsler ME, Szefler SJ, Ortega VE, et al. Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. N Engl J Med 2019; 381:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 2003; 40:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006; 97:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261:3273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014; :CD003137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H, Le Roux P, Bjåmer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130:1733.
          </a>
         </li>
         <li class="breakAll">
          2019 GINA Report. Global Stragegy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szefler SJ, Murphy K, Harper T 3rd, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook AL, Kinane TB, Nelson BA. Tiotropium use in pediatric patients with asthma or chronic cough: a case series. Clin Pediatr (Phila) 2014; 53:1393.
          </a>
         </li>
         <li class="breakAll">
          Omalizumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf (Accessed on July 13, 2016).
         </li>
         <li class="breakAll">
          Dupilumab https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s031lbl.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review. Pediatr Allergy Immunol 2017; 28:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Pouliquen I, Austin D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol 2019; 54:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol 2019; 144:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022; 400:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75:1023.
          </a>
         </li>
         <li class="breakAll">
          Dupilumab FDA approval https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761055Orig1s031ltr.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med 2021; 385:2230.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (Accessed on June 27, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lupia T, Scabini S, Mornese Pinna S, et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist 2020; 21:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahdavinia M, Foster KJ, Jauregui E, et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract 2020; 8:2388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol 2020; 146:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Foer D, Bates DW, et al. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol 2020; 146:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol 2020; 146:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc 2020; 17:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calmes D, Graff S, Maes N, et al. Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. J Allergy Clin Immunol Pract 2021; 9:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal JA, Awan SF, Fintzi J, et al. Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019. Ann Allergy Asthma Immunol 2021; 126:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JM, Koh HY, Moon SY, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol 2020; 146:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussein MH, Elshazli RM, Attia AS, et al. Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients. J Asthma 2022; 59:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou CC, Morphew T, Ehwerhemuepha L, Galant SP. COVID-19 infection may trigger poor asthma control in children. J Allergy Clin Immunol Pract 2022; 10:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E, et al. Impact of the COVID-19 pandemic in children with allergic asthma. J Allergy Clin Immunol Pract 2020; 8:3172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guijon OL, Morphew T, Ehwerhemuepha L, Galant SP. Evaluating the impact of coronavirus disease 2019 on asthma morbidity: A comprehensive analysis of potential influencing factors. Ann Allergy Asthma Immunol 2021; 127:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timberlake DT, Strothman K, Grayson MH. Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019. Curr Opin Allergy Clin Immunol 2021; 21:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amat F, Delaisi B, Labbé JP, et al. Asthma may not be a risk factor for severe COVID-19 in children. J Allergy Clin Immunol Pract 2021; 9:2478.
          </a>
         </li>
         <li class="breakAll">
          https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/.
         </li>
         <li class="breakAll">
          https://college.acaai.org/acaai-statement-covid-19-and-asthma-allergy-and-immune-deficiency-patients-3-12-20.
         </li>
         <li class="breakAll">
          https://education.aaaai.org/sites/default/files/COVID19_US%20FINAL.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milgrom H, Bender BG. Psychologic side effects of therapy with corticosteroids. Am Rev Respir Dis 1993; 147:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godfrey S, Balfour-Lynn L, Tooley M. A three- to five-year follow-up of the use of the aerosol steroid, beclomethasone dipropionate, in childhood asthma. J Allergy Clin Immunol 1978; 62:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godfrey S, Balfour-Lynn L, König P. The place of cromolyn sodium in the long-term management of childhood asthma based on a 3- to 5-year follow-up. J Pediatr 1975; 87:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006; :CD004108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro GG, Sharpe M, DeRouen TA, et al. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol 1991; 88:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newth CJ, Newth CV, Turner JA. Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. Aust N Z J Med 1982; 12:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Springer C, Goldenberg B, Ben Dov I, Godfrey S. Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma. J Allergy Clin Immunol 1985; 76:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Wouden JC, Tasche MJ, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev 2003; :CD002173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006; :CD003558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper GD, Neill P, Vathenen AS, et al. A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma. Respir Med 1990; 84:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svendsen UG, Frølund L, Madsen F, Nielsen NH. A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma. J Allergy Clin Immunol 1989; 84:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bel EH, Timmers MC, Hermans J, et al. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990; 141:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groot CA, Lammers JW, Molema J, et al. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water. Eur Respir J 1992; 5:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981; 304:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magnussen H, Reuss G, Jörres R. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987; 136:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18:143.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5744 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3). 2012. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on August 31, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines (Accessed on January 25, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22536582" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22536582" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1579137" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880315" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Glucocorticoid therapy for asthma: clinical pharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17095339" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19117903" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Inhaled corticosteroids and asthma control in children: assessing impairment and risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19254986" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18990678" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Severe exacerbations and decline in lung function in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27713266" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Inhaled Corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687711" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-term inhaled corticosteroids in preschool children at high risk for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19167726" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621371" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Inhaled corticosteroids: benefits and risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214958" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8024295" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Importance of the inhalation device on the effect of budesonide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19221157" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Managing childhood asthma: challenge of preventing exacerbations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20808979" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Airway remodelling in asthma: from benchside to clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19387034" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Remodeling in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908411" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11027739" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term effects of budesonide or nedocromil in children with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687712" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intermittent inhaled corticosteroids in infants with episodic wheezing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16935686" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18405951" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19912549" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lung function at 10 yrs is not improved by early corticosteroid treatment in asthmatic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450613" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ciclesonide versus other inhaled corticosteroids for chronic asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8765812" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9017785" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329408" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Childhood asthma and allergic rhinitis: the role of leukotrienes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9603110" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The role of leukotriene modifiers in the treatment of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20197425" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24089325" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22958412" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2574732" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7909853" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10469776" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10071526" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20164771" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731027" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Potential masking effects of salmeterol on airway inflammation in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9309980" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27579634" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27579634" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29554174" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29554174" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18214538" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592685" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592685" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15106175" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2189367" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1575550" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Inhaled budesonide for chronic wheezing under 18 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8215545" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of budesonide in severe asthmatics aged 1-3 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1975851" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Inhaled budesonide for treatment of recurrent wheezing in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3044506" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Controlled trial of budesonide given by the nebuhaler in preschool children with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466238" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14754977" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9679845" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26032474" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19594937" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28102056" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31194879" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085698" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15542792" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533366" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17218573" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The effect of montelukast on bronchial hyperreactivity in preschool children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9555757" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16126052" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16387583" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17140647" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983871" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16061590" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696076" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19946008" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21211651" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17507711" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clinical Decisions. Treatment of mild persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18192640" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19206182" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Recommendations for treatment of intermittent mild persistent asthma in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22111718" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Daily or intermittent budesonide in preschool children with recurrent wheezing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17634183" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7488811" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21324520" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450606" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20674830" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27551328" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The use of inhaled corticosteroids in pediatric asthma: update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7913155" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen&amp;Hanburys Limited UK Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10400478" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630590" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9227720" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9358137" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9167559" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11368732" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19824054" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26594816" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076961" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27579641" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Safety of Long-Acting Beta-Agonists in Children with Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31553835" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14529097" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12877449" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17042148" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2716163" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : How often is medication taken as prescribed? A novel assessment technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24459050" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17166990" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17166990" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189771" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567277" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Tiotropium use in pediatric patients with asthma or chronic cough: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567277" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Tiotropium use in pediatric patients with asthma or chronic cough: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567277" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Tiotropium use in pediatric patients with asthma or chronic cough: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28692145" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31502421" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425781" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35964610" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32034960" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32034960" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34879449" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34879449" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32156648" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32417445" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Asthma prolongs intubation in COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32554082" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32735807" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32771560" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Asthma among hospitalized patients with COVID-19 and related outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32864985" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33038592" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732333" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33059035" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32810517" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33504226" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35487371" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : COVID-19 infection may trigger poor asthma control in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32730834" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Impact of the COVID-19 pandemic in children with allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33775900" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Evaluating the impact of coronavirus disease 2019 on asthma morbidity: A comprehensive analysis of potential influencing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33399389" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852880" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Asthma may not be a risk factor for severe COVID-19 in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852880" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Asthma may not be a risk factor for severe COVID-19 in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852880" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Asthma may not be a risk factor for severe COVID-19 in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852880" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Asthma may not be a risk factor for severe COVID-19 in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8430974" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Psychologic side effects of therapy with corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/712019" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : A three- to five-year follow-up of the use of the aerosol steroid, beclomethasone dipropionate, in childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/809561" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : The place of cromolyn sodium in the long-term management of childhood asthma based on a 3- to 5-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16856028" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Nedocromil sodium for chronic asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1955633" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6810863" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3924984" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917923" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Inhaled sodium cromoglycate for asthma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625584" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2177216" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2547858" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2153355" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1330678" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7003383" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : The value of maintenance theophylline in steroid-dependent asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3314612" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3365858" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Need for theophylline in severe steroid-requiring asthmatics.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
